卡介菌多糖核酸注射液对血管运动性鼻炎的疗效观察

目的:观察卡介菌多糖核酸注射液对血管运动性鼻炎的临床治疗效果和安全性.方法:60例临床拟诊为血管运动性鼻炎患者按随机单盲对照试验方法分为卡介菌多糖核酸组和对照组(2组各30例),卡介菌多糖核酸组给予卡介菌多糖核酸注射治疗,每次1.0 mg,每周2次,共2个月,必要时予氮卓斯汀鼻喷剂对症治疗.对照组单独给予氮卓斯汀鼻喷剂.每日2次,症状缓解后酌减.均随访至停药后6个月.观察并记录治疗后症状得分、药物评分及不良反应.结果:卡介菌多糖核酸注射治疗2个月刚结束时,卡介菌多糖核酸组症状得分及药物评分均明显低于对照组(P＜0.01).至6个月后末次随访时,卡介菌多糖核酸组较对照组症状得分稍低但差异无统计学意义(P＞0.05),药物评分明显低于对照组(P＜0.01).卡介菌多糖核酸注射时不良反应仅1例诉有局部疼痛.结论:卡介菌多糖核酸是血管运动性鼻炎的一种安全有效的治疗方法.

Efficacy evaluation of polysaccharide nucleic acid-fraction of BCG on vasomotor rhinitis

Objective:To investigate the efficacy and safety of polysaccharide nucleic acid-fraction(BCG-PSN)in the treatment of vasomotor rhinitis.Method:Sixty patients were randomly divided into BCG-PSN group(n=30)and control group(n=30).The patients in BCG-PSN group were administered with BCG-PSN 1.0 mg twice a week for two months,and intranasal azelastine was used if needed.The patients in control group were administered with intranasal azelastine solely twice a day,which could be decreased with the symptom relief.Follow-up was 6 months.Symptom and medication scores were recorded.Side effects were registered.Result:The symptom and medication scores of BCG-PSN group were significantly lower than that of control group(P<0.01)after BCG-PSN treatment.There was no significant difference in symptom score between the two groups at 6 months after BCG-PSN treatment(P>0.05),while the medication score of BCG-PSN group was still much lower than that of control group(P<0.01).No serious adverse events were reported in BCG-PSN group except for local pain on the injection place in one patient.Conclusion:BCG-PSN is effective and safe in the treatment of vasomotor rhinitis.